Get the Stockscreener App
31.02
1.15%
-0.305
Cytokinetics Inc stock is traded at $31.02, with a volume of 598.28K.
It is down -1.15% in the last 24 hours and down -27.73% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$31.32
Open:
$31.41
24h Volume:
598.28K
Relative Volume:
0.29
Market Cap:
$3.70B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-5.8964
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
+1.38%
1M Performance:
-27.73%
6M Performance:
-40.30%
1Y Performance:
-36.97%
1-Day Range:
$30.26
$31.42
1-Week Range:
$29.81
$31.42
52-Week Range:
$29.31
$61.38
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
30.99 | 3.64B | 18.47M | -589.53M | -399.80M | -5.26 |
|
ONC
Beone Medicines Ltd Adr
|
247.11 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.43 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.55 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.53 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics (CYTK) Stock Update: Mizuho Lowers Price Target | C - GuruFocus
Cytokinetics to Participate in the Jefferies Global Healthcare Conference - TradingView
Cytokinetics Management Reveals Latest Updates at Jefferies Healthcare ConferenceLive Webcast Available - Stock Titan
Cytokinetics (CYTK) Gets Price Target Reduction from Mizuho Analyst | CYTK Stock News - GuruFocus
Mizuho Cuts Price Target on Cytokinetics to $84 From $103, Keeps Outperform Rating - marketscreener.com
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment landscape - Investing.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics at RBC Conference: Strategic Insights on Drug Development By Investing.com - Investing.com Canada
Protect Your Investment: Contact Levi & Korsinsky About the Cytokinetics, Incorporated (CYTK) Investigation - ACCESS Newswire
BNP Paribas Financial Markets Trims Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Spinal Muscular Atrophy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com
Cytokinetics (CYTK) Showcases Promising Aficamten Data for HCM T - GuruFocus
Cytokinetics (CYTK) Showcases Promising Aficamten Data for HCM Treatment | CYTK Stock News - GuruFocus
Cytokinetics Presents Additional Data Related to Aficamten at th - GuruFocus
Cytokinetics Announces SEQUOIA-HCM Analysis Results Highlighting Aficamten's Efficacy and Disparities in Hypertrophic Cardiomyopathy Outcomes Across Patient Demographics - Nasdaq
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress - The Manila Times
Clinical Trial Success: Aficamten Delivers Consistent Results Across All HCM Patient Groups in Global Study - Stock Titan
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Ru - GuruFocus
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView
Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance
Cytokinetics (NASDAQ:CYTK) Upgraded at Cantor Fitzgerald - Defense World
Cytokinetics (NASDAQ:CYTK) Earns Buy Rating from Needham & Company LLC - Defense World
Insider Sell: Muna Bhanji Sells 1,454 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics to Host Symposium on Contemporary Landscapes in Mus - GuruFocus
Cytokinetics (CYTK) to Host Muscle Biology Symposium in 2025 | C - GuruFocus
Cytokinetics (CYTK) to Host Muscle Biology Symposium in 2025 | CYTK Stock News - GuruFocus
Exclusive Muscle Biology Summit: Genentech, Stanford, and Penn Leaders Join Cytokinetics Research Symposium - Stock Titan
Bluebird extends deal deadline; Affimed files for insolvency - BioPharma Dive
Needham Reiterates Buy Rating on Cytokinetics (CYTK) with $72 Price Target | CYTK Stock News - GuruFocus
Cytokinetics builds its best-in-class case for aficamten - biocentury.com
Cytokinetics (CYTK) Rallies as Phase 3 Trial Succeeds for Lead D - GuruFocus
Stifel maintains confidence in Cytokinetics stock post-trial success By Investing.com - Investing.com Canada
Cytokinetics Unusual Options Activity - Nasdaq
Cytokinetics gets an ‘incremental’ win for delayed heart drug - Endpoints News
Cytokinetics stock rises on Phase 3 trial win (CYTK:NASDAQ) - Seeking Alpha
Cytokinetics (CYTK) Reports Positive Results from Phase 3 Clinical Trial | CYTK Stock News - GuruFocus
Cytokinetics Reports Positive Results From Phase 3 MAPLE-HCM Study - Nasdaq
Cytokinetics Announces Positive Topline Results From MAPLE-HCM | - GuruFocus
Cytokinetics Announces Positive Topline Results From MAPLE-HCM | CYTK Stock News - GuruFocus
Cytokinetics Announces Positive Topline Results From MAPLE-HCM - The Manila Times
Aficamten outperforms beta blocker in HCM trial - Investing.com
Aficamten outperforms beta blocker in HCM trial By Investing.com - Investing.com India
Cytokinetics' heart disease drug meets main goal in late-stage study - marketscreener.com
Dimensional Fund Advisors LP Trims Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics, Incorporated Being Investigated on Behalf of Cytokinetics, Incorporated Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Louisiana First News
5,400 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Bought by Raymond James Financial Inc. - Defense World
Cytokinetics, Incorporated Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for Details- CYTK - ACCESS Newswire
FY2025 EPS Estimates for Cytokinetics Lowered by Analyst - Defense World
Barclays Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $53.00 - Defense World
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
May 20 '25 |
Sale |
31.98 |
2,000 |
63,960 |
140,255 |
| Blum Robert I | President & CEO |
May 16 '25 |
Sale |
30.93 |
5,000 |
154,650 |
412,629 |
| Bhanji Muna | Director |
May 15 '25 |
Sale |
29.73 |
1,454 |
43,227 |
23,510 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):